Lifeboat Foundation

How we adapt to aging late in life may be genetically influenced, according to a study led by a psychologist at the University of California, Riverside.

The research, published in Aging Cell, has implications for how epigenetic factors relate to aging. Epigenesis is a process in which chemicals attached to DNA control its activity. Epigenetic changes, which can be passed on to offspring, may be critical to accelerated aging as well as declines in cognitive and physical functioning that often accompany aging. Epigenetic modifications resulting in altered gene expression may occur due to a number of biological processes, including one the researchers focused on: DNA methylation.

In DNA methylation, methyl groups are added to the DNA molecule. DNA has four different types of nucleotides: A, T, G, and C. DNA methylation occurs at the C bases of eukaryotic DNA. Changes in DNA methylation correlate strongly with aging.

Editor’s note: A recording of this virtual event is embedded above.

Artificial intelligence is proving a potent weapon against the pandemic, enabling researchers to comb through massive data sets to understand the virus and how to combat it. From drug development to immune response, STAT’s Casey Ross will talk to researchers and AI experts about how AI is accelerating a worldwide effort to crack Covid-19’s molecular code.

Featured Speakers:

Most of us are now familiar with apps that track what’s known as our ‘digital biomarkers’. These include the steps, we’ve taken, our heart rate, and our weight. In recent years startups have appeared which can, in a relatively turnkey manner, track our ‘biomedical markers’, such as cholesterol levels, for instance. Few, however, are seeking to combine the two to get a 360-degree view of how our bodies are doing.

Into this gap steps Humanity Inc., which will seek to do exactly that. Founded by two seasoned entrepreneurs, Humanity will combine digital and biomedical biomarkers into a consumer app that will fully launch next year.

Today it announces it’s initial seed fundraise of $2.5m, in a round led by Boston fund One Way Ventures and the legendary and long-time HealthTech Angel investor Esther Dyson, among others.

Honey appears to be a preferable treatment for cough or cold symptoms rather than antibiotics and over-the-counter medicines, according to a new systematic review that’s looked at the results from 14 previous studies — but the conclusions may not be quite so clear-cut as they appear at first.

“Honey is a frequently used lay remedy that is well known to patients,” write the researchers from the University of Oxford in the UK. “It is also cheap, easy to access and has limited harms.”

One particular area of interest is the comparison of honey to antibiotics. With antibiotics often causing side effects and antibiotic resistance on the rise, there are multiple advantages to using honey as an alternative remedy, the authors of the review point out.

Summary: Researchers identified a group of closely related genes that capture molecular links between Alzheimer’s and LATE, a common brain disorder that mimics Alzheimer’s symptoms.

Source: Brigham and Women’s Hospital

Alzheimer’s disease is one of the most common causes of dementia, and while most people might know someone who is affected by it, the genetic factors behind the disease are less known. A new study by investigators from Brigham and Women’s Hospital uncovered a group of closely related genes that may capture molecular links between Alzheimer’s disease and Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, a recently recognized common brain disorder that can mimic Alzheimer’s symptoms. LATE is often combined with Alzheimer’s disease to cause a more rapid cognitive decline. The study’s results are published in Neuron.

Nearly three-quarters of older adults with dementia have filled prescriptions for medicines that act on their brain and nervous system, but aren’t designed for dementia, a new study shows.

That’s despite the special risks that such drugs carry for older adults—and the lack of evidence that they actually ease the dementia-related behavior problems that often prompt a doctor’s prescription in patients with Alzheimer’s disease and related disorders. In fact, some of the drugs have been linked to worse cognitive symptoms in old adults.

The study looks at several classes of psychoactive drugs, including ones that the federal government has actively encouraged nursing homes to limit using in residents with dementia. The new study suggests a need to reduce prescribing to people living at home with dementia, too.

“I HOPE THIS STUDY CHANGES THE DIALOG AROUND HERPES RESEARCH AND OPENS UP THE IDEA THAT WE CAN START THINKING ABOUT CURE, RATHER THAN JUST CONTROL OF THE VIRUS.”

In a landmark study, researchers have successfully used gene editing to remove the oral herpes virus (HSV-1) in mice.

While previous research has mostly focused on treating and suppressing the sometimes painful symptoms of herpes, this study took a more radical approach by attempting to eliminate the virus altogether.

Continue reading “Scientists Use Gene-Hacking to Seemingly Cure Herpes in Mice” »

Scientists hope the CRISPR-based therapy could treat neurodegenerative disease.

Scientists investigating Alzheimer’s treatments at the Salk Institute have uncovered some key mechanisms that enable an experimental drug to reverse memory loss in mouse models of the disease. The discovery not only bodes well for the possibility of clinical trials, but provides researchers with a new target to consider in the wider development of compounds to counter the degenerative effects of the condition.

The research centers on a drug called CMS121, which is a synthetic version of a chemical called fisetin that occurs naturally in fruits and vegetables. The Salk team’s previous studies concerning CMS121 have produced some very promising results, with one paper published last year describing how the drug influences age-related metabolic pathways in the brain, protecting against the type of degeneration associated with Alzheimer’s. This followed earlier studies demonstrating how fisetin can prevent memory loss in mice engineered to develop Alzheimer’s.

Work continues at Salk to understand how exactly fisetin and the synthetic variant CMS121 produces these anti-aging effects on the brain. In their latest study, the researchers again turned to mice engineered to develop Alzheimer’s, which were administered daily doses of CMS121 from the age of nine months. This is the equivalent to middle age in humans, with the mice already exhibiting learning and memory problems before the treatment began.